Baroda BNP Paribas Dividend Yield Fund
Direct · GrowthAI Summary
The fund's 1Y SIP XIRR of 4.07% trails the category average of 9.98% by a wide margin, indicating underperformance versus dividend yield peers. However, it has outperformed the NIFTY 50 on a lump-sum basis across all periods, with a 1Y fund CAGR of -4.36% against the benchmark's -11.43% and positive alpha of 4.28%. Calendar year returns have been uneven, swinging from -6.63% in 2024 to 7.05% in 2025 and -5.98% in 2026.
The fund exhibits defensive characteristics with a beta of 0.84-0.88 and a downside capture of 81.82% over 1Y, meaning it has fallen significantly less than the NIFTY 50 in declining markets. The maximum drawdown of just -0.18% with one drawdown event suggests limited recent loss severity, though the 154-day drawdown duration without full recovery indicates a prolonged flat period. The 1Y Calmar ratio of 0.24 reflects modest risk-adjusted returns given the weak absolute performance.
The portfolio is diversified across 44 holdings with a reasonable top-10 concentration of roughly 41% of NAV, led by Reliance Industries (6.5%) and a meaningful banking allocation of 16.7% across ICICI, HDFC, and Kotak Mahindra Bank. Pharmaceuticals & Biotechnology is the second-largest sector at 13.0%, providing a defensive tilt consistent with the dividend yield mandate. Sector spread across banks, pharma, IT, auto components, and petroleum reduces single-sector risk.
The fund's 1Y SIP XIRR of 4.07% places it well below the category average of 9.98%, suggesting it has lagged most dividend yield peers over the recent period. Its consistent outperformance versus the NIFTY 50 across 1Y to 15Y horizons, with upside capture near 90% and downside capture below 88%, points to a defensive, capital-preservation orientation rather than category-leading returns. Long-term alpha turns slightly negative (-0.59% over 15Y), indicating benchmark-relative strength has come mainly from downside protection rather than sustained excess returns.
This fund suits conservative equity investors seeking dividend-yield-oriented exposure with lower volatility than the broad market, given its beta below 0.9 and strong downside capture. A time horizon of at least 5-7 years is appropriate, as lump-sum CAGRs remain negative over shorter windows and the fund's value emerges through drawdown mitigation over full market cycles. Investors should have low-to-moderate risk tolerance and should not expect category-beating returns in strong bull markets, where its ~90% upside capture will lag.
- Strong downside protection with 1Y downside capture of 81.82% versus the NIFTY 50, cushioning losses in weak markets
- Consistent benchmark outperformance across all measured horizons, including 1Y alpha of 4.28% and fund CAGR of -4.36% versus the benchmark's -11.43%
- Well-diversified 44-stock portfolio with a defensive tilt toward banks (16.7%) and pharmaceuticals (13.0%)
- 1Y SIP XIRR of 4.07% significantly trails the category average of 9.98%, indicating underperformance versus dividend yield peers
- Negative lump-sum CAGRs across all horizons (e.g., -4.36% over 1Y) and a max drawdown still unrecovered after 154 days point to weak absolute return generation
- Long-term alpha turns negative from 5Y onward (e.g., -0.20% at 5Y, -0.59% at 15Y), suggesting limited sustained excess return over the benchmark
Generated on 21-10-2026, 3:08 AM. Verify before investing.
Gives more importance to longer time periods (10Y, 20Y) than shorter ones (1Y, 3Y). This balances out recent outperformance and gives a more realistic picture of what long-term returns might look like.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.
| Duration | Invested | Median Value | XIRR | Min XIRR | Max XIRR |
|---|---|---|---|---|---|
| 1 Year | ₹12.00 L | ₹12.23 L | 4.4% | -15.1% | 17.2% |
SIP returns vs benchmark & category
Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.
| Duration | Fund SIP XIRR | NIFTY 50 | Category avg | Fund edge |
|---|---|---|---|---|
| 1 Year | 4.4% | 14.3% | 9.9% | -9.9% |
| Duration | Mean | Median | Min | Max | Sharpe | Sortino | % Positive | Cat. Mean | Cat. Median |
|---|---|---|---|---|---|---|---|---|---|
| 1 Year | 4.2% | 4.0% | -7.1% | 17.1% | -0.47 | -0.47 | 81% | — | — |
Calmar Ratio by Duration
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +3.16 | 0.85 | 89.3% | 83.3% | -6.6% | -12.7% |
| 3 Years | -0.18 | 0.88 | 89.9% | 88.6% | -2.8% | -3.8% |
| 5 Years | -0.42 | 0.88 | 89.9% | 88.6% | -1.7% | -2.3% |
| 7 Years | -0.53 | 0.88 | 89.9% | 88.6% | -1.2% | -1.7% |
| 10 Years | -0.61 | 0.88 | 89.9% | 88.6% | -0.8% | -1.2% |
| 12 Years | -0.64 | 0.88 | 89.9% | 88.6% | -0.7% | -1.0% |
| 15 Years | -0.67 | 0.88 | 89.9% | 88.6% | -0.6% | -0.8% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | Reliance Industries Limited | 6.50% |
| 2 | ICICI Bank Limited | 5.49% |
| 3 | HDFC Bank Limited | 4.85% |
| 4 | Larsen & Toubro Limited | 4.73% |
| 5 | Torrent Pharmaceuticals Limited | 4.33% |
| 6 | Divi's Laboratories Limited | 3.49% |
| 7 | GlaxoSmithKline Pharmaceuticals Limited | 3.28% |
| 8 | Radico Khaitan Limited | 3.25% |
| 9 | Hero MotoCorp Limited | 2.85% |
| 10 | Kotak Mahindra Bank Limited | 2.68% |